6/28/23, 12:05 AM AIRTRIP Pathway Feedback Search Clinical Topics Home Studies AIRTRIP AIRTRIP Disease Acute pericarditis Trial question What is the effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence? Study design Multi-center Double blinded RCT Population Characteristics of study participants 67.0% female N = 21 33.0% male 21 patients (14 female, 7 male) Inclusion criteria: patients with recurrent pericarditis, with 3 previous recurrences, elevation of CRP, colchicine resistance, and corticosteroid dependence and were administered anakinra ad at a dose of 2 mg/kg per day, up to 100 mg for 2 months Key exclusion criteria: pregnant or lactating; history of immunodepression, including a positive human immunodeficiency virus test result; positive QuantiFERON (QFT-TB G In-Tube) test result or positive purified protein derivative test result ( 5 mm induration) after the first attack of pericarditis; live vaccinations within 3 months prior to the start of the trial; history of malignancy of any organ system, treated or untreated, within the past 5 years; history of significant other medical conditions that in the investigator's opinion would exclude a patient from participating in this trial; or history of recurrent and/or evidence of active bacterial, fungal, or viral infection(s) https://web.pathway.md/studies/recnFBmiCwFuAeiMj 1/2 6/28/23, 12:05 AM AIRTRIP Pathway Interventions N=11 anakinra (continued treatment at a dose of 2 mg/kg per day, up to 100 mg SC for another 6 months) N=10 placebo (switched to identical placebo for another 6 months) Primary outcome Recurrent pericarditis 90.0 % 90 67.5 % 45.0 % Significant decrease 22.5 % NNT = 1 18.2 0.0 % Anakinra Placebo Significant decrease in recurrent pericarditis (18.2% vs. 90%; ARD -71.8, 95% CI -100 to -42) Safety outcomes Significant difference in transient local skin reactions (95.2% vs. 0). Conclusion In patients with recurrent pericarditis, with 3 previous recurrences, elevation of CRP, colchicine resistance, and corticosteroid dependence and were administered anakinra ad at a dose of 2 mg/kg per day, up to 100 mg for 2 months, anakinra was superior to placebo with respect to recurrent pericarditis. Reference Brucato A, Imazio M, Gattorno M et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016 Nov 8;316(18):1906-1912. Open reference URL https://web.pathway.md/studies/recnFBmiCwFuAeiMj 2/2